Latest From KemPharm Inc.
Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Suboxone market share has declined with the at-risk launch of Dr. Reddy’s generic competitor, while Indivior awaits a court decision on a requested temporary restraining order against the launch.
Studies showing oxycodone could be extracted for intravenous use troubled advisory committee members, who worried it would result in the same types of adverse public health effects that led to market withdrawal of Endo’s Opana ER; panelists also were concerned about the ability to partially defeat Remoxy’s extended-release properties by chewing the product.
- Drug Discovery Tools
- Controlled Release
- Drug Delivery
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- KemPharm Inc.
- Senior Management
Travis C Mickle, PhD, Pres., CEO & Chmn.
R. LaDuane Clifton, CFO, Secretary & Treasurer
Christopher Lauderback, PhD, VP, Manufacturing
Sven Guenther, PhD, EVP, R&D
Gordon "Rusty" K Johnson, CBO
Rene A Braeckman, PhD, VP, Clinical Dev.
- Contact Info
Phone: (319) 665-2575
1180 Celebration Blvd.
Celebration, FL 34747
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.